Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532213) titled 'A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab' on April 8.

Study Type: Observational

Primary Sponsor: Janssen-Cilag A.G., Switzerland

Condition: Inflammatory Bowel Disease Colitis, Ulcerative Crohn Disease

Recruitment Status: Not recruiting

Date of First Enrollment: April 23, 2026

Target Sample Size: 50

To know more, visit https://clinicaltrials.gov/study/NCT07532213

Disclaimer: Curated by HT Syndication....